Comprehensive Antibody Efficacy Assessment Services

We utilize a variety of specificity assays, including western blot, immunofluorescence, and immunohistochemistry, to verify the specificity of the antibodies. These methods ensure the target recognition ability and specificity of antibodies and provide accurate detection results.

For assessing the stability of antibodies, we are open to the demand for testing at specified storage conditions and time points. We monitor the activity, potency, and cross-reactivity of antibodies to assess their performance in maintaining stability under varying conditions.

We perform a comprehensive analysis of antibodies using a variety of purity assays, such as mass spectrometry, capillary electrophoresis, and HPLC. These methods determine the purity, molecular weight and other relevant parameters of antibodies.

Our team will help you understand the immunomodulatory capabilities of antibodies by efficiently detecting secreted levels of cytokines and chemokines in a multiplexed format and assessing the effect of antibodies on cellular activity. Customized detection of multiple analytes in single wells is possible, further, extremely small volume requirements and high sensitivity allow for high throughput detection of cytokines.

ELISA technology is applied to provide highly sensitive antibody titer and affinity readings to perform endpoint analysis. The method helps you understand the ability of antibodies to recognize specific antigens and immune function.

Flow cytometry is adapted to a wide range of parametric determinations including, but not limited to, immunophenotyping, cell proliferation, and intracellular calcium flux assays, providing important information on the potency of antibodies in immune cell recognition and sorting.

Currently, approaches used for antibody concentration determination include ELISA, fluid-liquid-phase radioimmunoassay, fluid-liquid-phase mobility shift assay, and reporter gene assay. We have developed a variety of therapeutic antibody quantitative monitoring strategies based on indirect, antibody-competitive, and ligand-competitive methods of ELISA to aid in the determination of antibody concentrations in blood.

The development of immune checkpoint-based antibody drugs for several types of tumors and other diseases is also evolving and being optimized. In this regard, we also provide a service for evaluating the efficacy of immune checkpoint-based antibodies.